Business
Oncolytics Biotech® Appoints Jonathan Rigby to its Board of Directors
Oncolytics Biotech® Appoints Jonathan Rigby to its Board of Directors Cana...
About this update from Oncolytics Biotech Inc.
[{"type":"text","content":"\n \n \n \n Oncolytics Biotech® Appoints Jonathan Rigby to its Board of Directors\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prngen2{\nPADDING-RIGHT:0.17em; PADDING-LEFT:0.17em; VERTICAL-ALIGN: BOTTOM; BORDER-TOP:black 1pt; BORDER-RIGHT:black 1pt; BORDER-BOTTOM:black 1pt; BORDER-LEFT:black 1pt\n}\n.prnml4{\nMARGIN-TOP:0em; MARGIN-RIGHT:0em; MARGIN-BOTTOM:0em; MARGIN-LEFT:0.33em !IMPORTANT\n}\n.prnbcc{\nBORDER-COLLAPSE: COLLAPSE; BORDER-TOP:1pt black; BORDER-RIGHT:1pt black; BORDER-BOTTOM:1pt black; BORDER-LEFT:1pt black\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n Mr. Rigby is the Group Chief Executive Officer of Revolo Biotherapeutics and has three decades of experience in the pharmaceutical and biotechnology industries\n \n \n \n \n \n SAN DIEGO\n \n and\n \n CALGARY, AB\n \n \n ,\n \n \n Sept. 7, 2022\n \n \n /CNW/ -- Oncolytics Biotech\n \n ®\n \n Inc. (NASDAQ: ONCY) (TSX: ONC) today announced the appointment of\n \n Jonathan Rigby\n \n to its Board of Directors.\n \n \n \n \n \n \"Jonathan has successfully built, financed, listed, and led several life science companies across a range of therapeutic areas, and I am thrilled to welcome him to our Board,\" said Dr.\n \n Matt Coffey\n \n , President and Chief Executive Officer of Oncolytics Biotech Inc. \"His extensive executive leadership experience, together with his business development and commercial expertise, will guide us as we advance our breast and pancreatic cancer programs towards late-stage trials and work to deepen our relationships with leading biopharmaceutical companies. His background is highly complementary with those of our other Board members, and I look forward to beginning our work together.\"\n \n \n Mr. Rigby added, \"The opportunity to join Oncolytics at this crucial stage in the Company's evolution and help forge the Company forward to treat these terrible cancers is compelling. Extensive clinical data have demonstrated pelareorep's ability to provide a statistically significant survival benefit in breast cancer, its potential to synergi...